Molecure S.A.

WSE:MOC Stock Report

Market Cap: zł124.2m

Molecure Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Marcin Szumowski

Chief executive officer

zł367.2k

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownership0.6%
Management average tenure5.4yrs
Board average tenure4.4yrs

Recent management updates

Recent updates

Analysis Article Sep 06

We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article Aug 20

Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article Apr 20

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article Dec 01

We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article Jul 07

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article Mar 10

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article Aug 16

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article Nov 04

OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

OncoArendi Therapeutics S.A.'s ( WSE:OAT ) robust earnings report didn't manage to move the market for its stock. Our...
Analysis Article Feb 24

Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

Every investor in OncoArendi Therapeutics S.A. ( WSE:OAT ) should be aware of the most powerful shareholder groups...
Analysis Article Jan 02

Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, OncoArendi...

CEO

Marcin Szumowski

no data
Tenure
zł367,206
Compensation

Dr. Marcin Jan Szumowski, Ph D., is employed at Life Science Innovations Fund. He has been Chief Executive Officer and President of the Management Board at Molecure S.A. (formerly known as OncoArendi Thera...


Leadership Team

NamePositionTenureCompensationOwnership
Marcin Szumowski
Co-Founderno datazł367.21k0.57%
PLN 706.5k
Zbigniew Zaslona
Chief Scientific Officer & Member of Management Board4.4yrszł367.21k0.092%
PLN 113.9k
Piotr Iwanowski
Chief Medical Officer & Member of Management Board1.8yrszł122.47kno data
Agnieszka Rajczuk-Szczepanska
HR Director6.4yrszł271.21kno data
Adam Golebiowski
Co-Founder & VP of Research Chemistry14.4yrszł500.00kno data
Jacek Olczak
Co-Founder & Head of Medicinal Chemistryno datano datano data
Monika Czarnecka
Finance Director1.4yrsno datano data
Magdalena Tyszkiewicz
Head of CMC6.4yrsno datano data
5.4yrs
Average Tenure

Experienced Management: MOC's management team is seasoned and experienced (5.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Robert Oskard
Member of the Supervisory Boardless than a yearno datano data
Luke O'Neill
Member of Scientific Advisory Boardno datano datano data
Bart Lambrecht
Member of Scientific Advisory Boardno datano datano data
Tomasz Piec
Vice Chairman of the Supervisory Board6.4yrszł129.06kno data
Douglas Hay
Member of Scientific Advisory Boardno datano datano data
Paul Van Der Horst
Independent Chairman of the Supervisory Board4.4yrszł154.87k0.049%
PLN 60.3k
Nancy Van Osselaer
Independent Member of the Supervisory Board4.4yrszł129.06kno data
Pawel Trawkowski
Independent Member of the Supervisory Board4yrszł129.06kno data
4.4yrs
Average Tenure
59.5yo
Average Age

Experienced Board: MOC's board of directors are considered experienced (4.4 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/08 11:40
End of Day Share Price 2026/06/05 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Molecure S.A. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kamil KliszczBiuro maklerskie mBanku
Beata Szparaga-WasniewskaBiuro maklerskie mBanku
Lukasz KosiarskiIpopema Securities S.A.